What flavors will JUUL relaunch?
Short Answer
The model forecasts Mint as the most likely flavor for JUUL to relaunch in 2027, but assigns significantly lower odds (11.8% model vs 30.0% market) compared to the market.
1. Executive Verdict
- FDA authorization for JUUL2 flavored pods appears essential before 2027.
- JUUL filings offer no specific evidence for a Mint flavor relaunch.
- JUUL's financial stability concerns may hinder costly FDA applications.
- Only Virginia Tobacco and Menthol flavors were FDA authorized as of June 2026.
- A change in FDA flavor authorization appears the primary U.S. catalyst.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Mango | 9.0% | 2.4% | Mango may be relaunched by JUUL. |
| Mint | 30.0% | 11.8% | Mint may be relaunched by JUUL. |
| Cool Mint | 15.0% | 6.9% | Cool Mint may be relaunched by JUUL. |
| Cucumber | 21.0% | 10.8% | Cucumber may be relaunched by JUUL. |
| Crème Brûlée | 14.0% | 6.3% | Crème Brûlée may be relaunched by JUUL. |
Current Context
Mint and menthol flavors show the highest potential for U.S. relaunch. As of May 2026, only Virginia Tobacco and Menthol flavors, at both 3% and 5% nicotine concentrations, are authorized for sale in the U.S. following FDA approval in July 2025 [^][^][^]. Prediction markets indicate a 30% probability for a "Mint" relaunch and a 15% probability for a "Cool Mint" relaunch by January 1, 2027, with "Mint" resolving to "Yes" if "Cool Mint" is relaunched [^]. These markets, which show "Mint" and "Cool Mint" as the highest probabilities for a U.S. relaunch, are set to close by December 31, 2026, or upon an earlier release [^]. Any new mint-related flavors approved for the U.S. market are expected to be named as menthol or tobacco variations rather than their original "Mint" branding; JUUL has reportedly submitted an application for a new menthol flavor for its JUUL2 device, rumored to be similar to the old mint [^].
JUUL expands internationally and actively engages U.S. regulators. The JUUL2 device is currently available in the UK and awaits regulatory approval for the U.S. market [^][^]. In the UK, the JUUL2 expanded its flavor portfolio with Mango, Watermelon, Apple, and Lychee in October 2025, and a Peach flavor in January 2026 [^]. JUUL Labs demonstrates ongoing engagement with regulatory processes, having submitted comments in May 2026 regarding the FDA's March 2026 Draft Guidance on Applications for Flavored E-Cigarettes [^][^]. The company has also refocused its marketing strategy to a data-driven approach, targeting adult smokers aged 21 and over with an emphasis on harm reduction and age verification, moving away from broad social media campaigns [^]. From a financial perspective, JUUL Labs sought $1 billion in funding as of August 2023, with its valuation having decreased from $38 billion in 2018 to $450 million by July 2022, and reporting approximately $800 million in revenue for 2022 [^][^].
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
This prediction market, which tracks the probability of JUUL relaunching its Mango flavor by 2027, has been characterized by a sideways trend and significant volatility in response to regulatory news. The price has fluctuated within a range of 2.0% to 17.0%, starting at 8.0% and currently trading at 9.0%. A period of intense activity occurred at the end of May 2026, beginning with a drop from 10.0% to 2.0% as the market processed that an FDA authorization for fruit-flavored e-cigarettes was for companies other than JUUL. This was immediately followed by a sharp spike to a high of 16.0% on May 31, driven by renewed speculation that the FDA's approval of any fruit flavor was a positive signal for the entire category. However, this optimism was short-lived, as the price fell back to 9.0% on June 5 in what appears to be a market correction, factoring in the continued lack of any specific news or authorization for JUUL's fruit products.
The price action indicates key technical levels and reflects a speculative market sentiment. Resistance was established around the 16.0%-17.0% level, which capped the late-May rally, while support was found at 2.0% during the initial dip. The current price of 9.0% is hovering near the market's opening price, suggesting a return to a baseline sentiment of skepticism after a period of high volatility. The total volume of 1,250 contracts traded suggests moderate engagement. Overall, the chart indicates that traders see the relaunch of Mango as a low-probability event, but sentiment remains highly sensitive to any broader regulatory developments in the e-cigarette industry, even those not directly involving JUUL.
3. Significant Price Movements
Notable price changes detected in the chart, along with research into what caused each movement.
Outcome: Mango
📉 June 05, 2026: 8.0pp drop
Price decreased from 17.0% to 9.0%
What happened: The 8.0 percentage point drop in the "Mango" outcome for JUUL's potential relaunch on June 05, 2026, appears to be a market correction stemming from the continued absence of any official announcement or specific FDA authorization for JUUL's fruit-flavored products in the U.S. [^]. While the FDA authorized fruit-flavored vapes for another manufacturer in May 2026, initially sparking broader speculative interest for the category [^][^][^], this optimism for JUUL specifically lacked a direct catalyst by June 05, 2026 [^]. No specific social media activity on X or other platforms from key figures, nor new traditional news from major outlets, was identified on or around June 05, 2026, that directly caused this movement. Consequently, social media was irrelevant in causing this market shift.
📈 May 31, 2026: 14.0pp spike
Price increased from 2.0% to 16.0%
What happened: The primary driver of the 14.0 percentage point spike in the "Mango" outcome was the FDA's authorization of non-tobacco/non-menthol fruit-flavored vapes, including mango, for other companies in May 2026 [^]. This regulatory shift, which reportedly followed political pressure to authorize such flavors, signaled a potential softening in the overall stance towards fruit-flavored vape products [^]. Although this specific authorization did not include JUUL products [^], it likely increased optimism among prediction market participants regarding the eventual reintroduction of JUUL's "Mango" flavor. Social media activity was irrelevant as no related posts from key figures or viral narratives were identified in the available research.
📉 May 30, 2026: 8.0pp drop
Price decreased from 10.0% to 2.0%
What happened: The 8.0 percentage point drop in the "Mango" prediction market on May 30, 2026, was primarily driven by the market's re-evaluation of a traditional news announcement [^]. Earlier in May 2026, the FDA granted its first marketing authorization for fruit-flavored e-cigarettes (Mango and Blueberry) to competitor Glas, Inc., which initially sparked speculation about JUUL's future portfolio, leading to an early May market peak [^][^][^][^]. However, the subsequent price decline reflected a clearer understanding that this specific FDA approval did not apply to JUUL Labs [^][^]. Social media activity was not explicitly identified as a primary driver for this particular price drop.
Outcome: Cucumber
📈 May 22, 2026: 11.0pp spike
Price increased from 9.0% to 20.0%
What happened: The provided sources do not contain information identifying the cause of the 11.0 percentage point price spike for "Cucumber" flavor on May 22, 2026. While the U.S. FDA has authorized Virginia Tobacco and Menthol flavors for sale [^], and Juul Labs UK expanded its JUUL2 flavor portfolio with other variants like Mango and Watermelon in January 2026 [^], none of these reports mention cucumber or any specific event correlating with the May 22, 2026, market movement. Therefore, social media cannot be identified as a primary driver or contributing accelerant based on the available data.
4. Market Data
Contract Snapshot
The Mint market resolves to Yes if JUUL releases Mint, Cool Mint, or any other mint-related flavor to the public before January 1, 2027. If none of these events occur, the market resolves to No and closes by December 31, 2026, 11:59pm EST. Outcomes are verified from Juul.com.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Mint | $0.30 | $0.75 | 30% |
| Cucumber | $0.27 | $0.78 | 21% |
| Cool Mint | $0.19 | $0.86 | 15% |
| Crème Brûlée | $0.14 | $0.94 | 14% |
| Fruit Medley | $0.14 | $0.94 | 14% |
| Mango | $0.17 | $0.91 | 9% |
Market Discussion
The market discussion revolves around whether JUUL will relaunch popular flavors like Mint, Cool Mint, and potentially fruit flavors such as Mango. Traders supporting a relaunch point to recent FDA approvals for fruit-flavored vapes from other brands as a potential precedent for JUUL, and some believe FDA approval of menthol flavors paves the way for mint. However, a significant counter-argument emphasizes that menthol is distinct from mint, and mint might still be considered a disallowed flavor by the FDA.
5. What key milestones in the FDA's review of the JUUL2 device could serve as catalysts for a flavor relaunch before 2027?
| JUUL2 PMTA Submission | July 2023 [^][^] |
|---|---|
| JUUL2 Menthol Pod PMTA Status | Submitted [^] |
| Original JUUL Menthol Pod Authorization | July 17, 2025 [^] |
FDA authorization for JUUL2 and its flavored pods is essential. For a flavor relaunch concerning the JUUL2 device to occur before 2027, the FDA must grant marketing authorization for both the JUUL2 system and its specific flavored pods. JUUL submitted Premarket Tobacco Product Applications (PMTAs) for the JUUL2 system in July 2023 [^][^]. Additionally, JUUL has submitted a PMTA for a menthol next-generation platform pod designed exclusively for the JUUL2 device [^].
The FDA has not yet authorized JUUL2 or its flavors. While the FDA authorized the marketing of Menthol-flavored JUUL pods (3% and 5% nicotine) on July 17, 2025, alongside Virginia Tobacco-flavored pods, this authorization was specifically for the original JUUL device [^]. The FDA's review process for JUUL products previously included marketing denial orders issued on June 23, 2022. However, these orders were rescinded on June 6, 2024, effectively returning the PMTAs to a 'pending status' under substantive review [^][^]. Crucially, the available research indicates that the FDA has not authorized the marketing of the JUUL2 device or any flavored pods exclusively for the JUUL2 system.
6. What specific evidence in JUUL's regulatory filings supports the market consensus favoring a Mint or Cool Mint relaunch over other banned flavors?
| FDA Authorized Flavors | Menthol and Virginia Tobacco (3% and 5% nicotine) [^] |
|---|---|
| Total Authorized JUUL Products | 5 (JUUL device, Virginia Tobacco 3% and 5% pods, Menthol 3% and 5% pods) [^] |
| Mint/Cool Mint Status | Not currently authorized; would require separate FDA marketing authorization [^][^][^] |
JUUL's regulatory filings offer no specific evidence for a Mint or Cool Mint relaunch. The available public records from the U.S. Food and Drug Administration (FDA) explicitly support menthol as an authorized flavor for JUUL products, not mint or Cool Mint [^]. The FDA’s authorization on July 17, 2025, specifically approved the marketing of five JUUL e-cigarette products: the JUUL device, Virginia Tobacco pods (3% and 5% nicotine), and Menthol pods (3% and 5% nicotine) [^].
The FDA's technical review process did not recommend Mint or Cool Mint. The FDA’s Technical Project Lead (TPL) review for JUUL's Premarket Tobacco Product Applications (PMTAs) analyzed and specifically recommended marketing orders for JUULpods Menthol 3.0%, Menthol 5.0%, Virginia Tobacco 3.0%, Virginia Tobacco 5.0%, and the JUUL Device [^][^]. There was no corresponding recommendation for mint or Cool Mint products. Consequently, any market consensus suggesting a relaunch of "Mint" or "Cool Mint" is not supported by these specific FDA regulatory filings regarding granted or authorized flavors. Such a relaunch would be speculative and necessitate separate FDA marketing authorization via the PMTA pathway [^][^][^].
7. How does the FDA's regulatory framework for flavored e-cigarettes compare to the UK's, and what does this imply for Mango's U.S. relaunch prospects?
| US Flavor Regulation | Restrictive premarket authorization for non-tobacco flavors [^][^][^][^] |
|---|---|
| UK Flavor Regulation Trend | Moving towards stricter oversight, with potential future flavor and display restrictions [^][^][^] |
| Mango U.S. Relaunch Status | Faces substantial hurdles, no official FDA authorization as of June 2026 [^] |
The FDA imposes strict premarket authorization for flavored e-cigarettes. The U.S. Food and Drug Administration (FDA) employs a restrictive premarket authorization (PMTA) framework for non-tobacco flavored e-cigarettes. Manufacturers are required to demonstrate that such products provide an 'added benefit' to adult smokers when compared to tobacco-flavored options, while simultaneously minimizing risks to youth [^][^][^][^]. This stringent evidentiary burden creates significant challenges for any flavored e-cigarette seeking to relaunch in the U.S. market.
UK regulations are tightening, but flavored U.S. relaunch faces hurdles. In contrast to the U.S., the UK historically utilized a more permissive, notification-based system for e-cigarettes. However, the UK is now moving towards stricter regulation with the Tobacco and Vapes Act (2026), which may introduce future restrictions on flavors and product displays [^][^][^]. Given the FDA's high evidentiary standards, the prospects for a flavored U.S. relaunch, such as Mango, confront substantial obstacles [^][^][^]. While prediction markets have identified Mango as a potential target, there have been no official company announcements or FDA authorizations for these specific flavors as of June 2026 [^].
8. What public dockets and FDA databases can be used to track the progress of JUUL's pending Premarket Tobacco Product Applications (PMTAs)?
| Initial MDOs Issued | June 23, 2022 [^] |
|---|---|
| MDOs Administratively Stayed | July 5, 2022 [^] |
| MDOs Rescinded, Applications Pending | June 6, 2024 [^] |
FDA offers specific databases and pages to track JUUL’s PMTA progress. Key FDA resources for monitoring JUUL's pending Premarket Tobacco Product Applications (PMTAs) include the "Tobacco Products Marketing Orders" page for major decisions [^] and the "Update on FDA’s Scientific Review of JUUL Product Applications" page, which provides specific procedural updates regarding JUUL [^]. For broader application metrics and progress tracking, the "Tobacco Product Applications: Metrics & Reporting" page presents regularly updated metrics across various review phases, such as Acceptance, Filing, and Review/Action, and links to a searchable database [^]. Furthermore, underlying technical documentation and JUUL-related PMTA technical review and record documents, including PDFs detailing FDA review milestones, are accessible through FDA-hosted AccessData "searchtobacco" static documents [^].
JUUL's PMTA status evolved through MDOs, stays, and rescission. The FDA initially issued marketing denial orders (MDOs) for JUUL Labs Inc. on June 23, 2022 [^]. These MDOs were subsequently subjected to an administrative stay on July 5, 2022, and were officially rescinded on June 6, 2024 [^]. Following the rescission, JUUL's applications were returned to a pending status, indicating they are once again undergoing substantive review by the FDA [^].
9. How does JUUL Labs' current financial health impact its ability to fund the costly FDA application process for multiple flavors before 2027?
| Authorized Flavors (US) | Tobacco and menthol (as of June 2026) [^] |
|---|---|
| Former Company Valuation | $38 billion [^][^][^][^] |
| FDA Guidance for Non-Tobacco/Menthol Flavors | March 2026 (draft guidance issued) [^][^] |
JUUL's financial stability is a significant concern for funding FDA applications. The company's capacity to finance the expensive FDA application process required for various non-tobacco and non-menthol flavors before 2027 is directly impacted by its current financial state. Extensive restructuring measures, including substantial workforce reductions and multi-billion dollar settlements, were undertaken to prevent bankruptcy. Consequently, JUUL has become a diminished entity compared to its previous $38 billion valuation [^][^][^][^].
FDA regulations complicate JUUL's future flavor authorization efforts. As of June 2026, JUUL Labs is only authorized to sell tobacco and menthol flavored products in the United States, with no official timeline for reintroducing other flavors [^]. The FDA's draft guidance, issued in March 2026, establishes a rigorous and costly pathway for Premarket Tobacco Product Applications (PMTAs) for non-tobacco and non-menthol flavors [^][^]. This guidance significantly increases the expense and complexity of obtaining future flavor authorizations for companies like JUUL, as each potential flavor relaunch requires a separate, expensive FDA marketing authorization, further straining JUUL's financial resources [^].
10. What Could Change the Odds
Key Catalysts
The primary catalyst for JUUL in the U.S. market would be a change in FDA authorization regarding e-cigarette product flavors. As of June 5, 2026, the only JUUL e-cigarette products authorized by the U.S. FDA for marketing are the JUUL device, Virginia Tobacco-flavored JUULpods (3% and 5% nicotine), and Menthol-flavored JUULpods (3% and 5% nicotine) [^][^]. Prediction markets for a U.S. JUUL flavor relaunch in 2026 indicate bearish sentiment, with low probabilities assigned to the reintroduction of flavors such as Mango or Mint, largely due to persistent regulatory hurdles and the lack of FDA authorization for any flavors other than tobacco and menthol [^]. JUUL Labs has been actively expanding its flavor portfolio in international markets, such as the UK, where it introduced JUUL2 Peach pods in January 2026, following the launch of several single-fruit flavors in late 2025; however, these do not impact U.S. availability [^][^].
Another significant catalyst involves JUUL's financial and legal challenges. The company faces considerable financial pressure in 2026 due to ongoing multi-state settlement obligations exceeding $1.7 billion [^]. Additionally, active litigation, including an antitrust trial scheduled for September 2026, presents further potential impacts on the company's market position [^][^].
Key Dates & Catalysts
- Expiration: January 08, 2027
- Closes: January 01, 2027
11. Decision-Flipping Events
- Trigger: The primary catalyst for JUUL in the U.S.
- Trigger: Market would be a change in FDA authorization regarding e-cigarette product flavors.
- Trigger: As of June 5, 2026, the only JUUL e-cigarette products authorized by the U.S.
- Trigger: FDA for marketing are the JUUL device, Virginia Tobacco-flavored JUULpods (3% and 5% nicotine), and Menthol-flavored JUULpods (3% and 5% nicotine) [^] [^] .
13. Historical Resolutions
No historical resolution data available for this series.
